ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those ...
3 hours ago
0
3









